Skip to Content

Rule

New Animal Drugs; Change of Sponsor

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for three new animal drug applications (NADAs) from Sweetlix LLC to Ridley U.S. Holdings, Inc.

DATES:

This rule is effective October 28, 2004.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

David R. Newkirk, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6967, e-mail: david.newkirk@fda.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Sweetlix LLC, 175 South Main St., suite 150, Salt Lake City, UT 84111, has informed FDA that it has transferred ownership of, and all rights and interest in, the following three approved NADAs to Ridley U.S. Holdings, Inc., 424 North Riverfront Dr., P.O. Box 8500, Mankato, MN 56002-8500:

Application Number21 CFR SectionTrade Name
NADA 033-733520.1840Sweetlix Bloat Guard Block
Start Printed Page 62811
NADA 109-471520.1448aCattle Block M
NADA 136-214520.1846Enproal Bloat Blox

Accordingly, the agency is amending the regulations in 21 CFR 520.1448a, 520.1840, and 520.1846 to reflect the transfer of ownership.

Following these changes of sponsorship, Sweetlix LLC is no longer the sponsor of an approved application. In addition, Ridley U.S. Holdings, Inc., is not currently listed in the animal drug regulations as a sponsor of an approved application. Accordingly, § 510.600(c) is being amended to remove the entries for Sweetlix LLC and to add entries for Ridley U.S. Holdings, Inc.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 510—NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority Start Amendment Part

2. Section 510.600 is amended in the table in paragraph (c)(1) by removing the entry for “Sweetlix LLC” and by alphabetically adding an entry for “Ridley U.S. Holdings, Inc.” and in the table in paragraph (c)(2) by removing the entry for “036904” and by adding an entry for “067949” to read as follows:

End Amendment Part
Names, addresses, and drug labeler codes of sponsors of approved applications.
* * * * *

(c) * * *

(1) * * *

Firm name and addressDrug labeler code
*    *    *    *    *
Ridley U.S. Holdings, Inc., 424 North Riverfront Dr., P.O. Box 8500, Mankato, MN 56002-8500067949
*    *    *    *    *

(2) * * *

Drug labeler codeFirm name and address
*    *    *    *    *
067949Ridley U.S. Holdings, Inc., 424 N. Riverfront Dr., P.O. Box 8500, Mankato, MN 56002-8500
*    *    *    *    *
Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

3. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

4. Section 520.1448a is amended in paragraph (a)(2) by removing “036904” and by adding in its place “No. 067949.”

End Amendment Part
[Amended]
Start Amendment Part

5. Section 520.1840 is amended in paragraph (b)(3) by removing “036904” and by adding in its place “067949.”

End Amendment Part
[Amended]
Start Amendment Part

6. Section 520.1846 is amended in paragraph (b) by removing “050112” and by adding in its place “067949.”

End Amendment Part Start Signature

Dated: October 20, 2004.

Steven D. Vaughn,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 04-24112 Filed 10-27-04; 8:45 am]

BILLING CODE 4160-01-S